Polycystic ovary syndrome (PCOS) is one of the most common and more complex conditions that occur in adolescent to reproductive age women with hyperandrogenic anovulation. The increasing research on neurological, endocrine and metabolic disorders in PCOS and their long-term impact on women’s quality of life in the last decade or so has led to a greater awareness that treatment of PCOS is not only a solution to the immediate problem of menstrual disorders and infertility, but also has important long-term implications for improving women’s quality of life. Diagnostic points: 1. anovulatory menstruation or menstrual disorders; 2. hyperandrogenic manifestations; 3. polycystic ovaries: increased ovarian volume suggested by ultrasound or anal ultrasound, with length (cm) × width (cm) × posterior diameter (cm)/2 greater than or equal to 6 ml, enhanced ovarian peritoneum, and more than 10 follicles of 2-9 mm diameter in the cortex Classification: 1. PCOS type I: hyperandrogenic type is predominant. PCOS type Ia: androgens mainly originate from the ovaries, clinically seen as scanty menstruation or amenorrhea, hirsutism, acne, centripetal obesity. PCOS type Ib: Androgens mainly come from the ovaries and adrenal cortex, clinically amenorrhea is the main cause, and the body is thick and obese. 2. PCOS type II: high androgen and high insulin type is predominant. PCOS type IIa: clinically predominantly amenorrhea, hyperphagia, hirsutism, marked centripetal obesity, family history of hypertension or diabetes. PCOS type IIb: persistent amenorrhea, hypertrichosis, hyperphagia, marked centripetal obesity, family history of hypertension or diabetes mellitus.